부산대학교 도서관

The reported prevalence of clinical hyperthyroidism in pregnancy is 0.1% to 0.4%. For several decades, pregnant women with this disorder have been treated with suppressive thyrostatic agents to prevent many potential complications of hyperthyroidism in pregnancy. The antithyroid drugs used include propylthiouracil and methimazole/carbimazole. For many years, physicians have been concerned about the fetal risks of these 2 drugs. Previous reports suggested an association between prenatal exposure to methimazole/carbimazole and congenital malformations or an embryopathy. The limited data available on the association between prenatal exposure to propylthiouracil and major congenital anomalies are conflicting.